Tectonic Therapeutic Inc（TECX）财务数据TECXTectonic Therapeutic Inc

Evaluating the bottom line, Tectonic Therapeutic, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -33.80%, provide a clear picture of how effectively TECX converts its operational activities into shareholder value.

In the context of the broader market, TECX competes directly with industry leaders such as ACTG and OWLS. With a market capitalization of $416.40M, it holds a leading position in the sector. When comparing efficiency, TECX's gross margin of N/A stands against ACTG's 49.81% and OWLS's 6.39%. Such benchmarking helps identify whether Tectonic Therapeutic, Inc. is trading at a premium or discount relative to its financial performance.

Tectonic Therapeutics has been experiencing consistent financial losses, with a net income of -$22.3 million in Q2 2026 and a negative EPS of -1.18. The company's current ratio remains strong at 22.29, indicating good short-term liquidity, but the overall financial performance is concerning due to ongoing losses.